| Schedule of Significant Expense Categories and Amounts Align with Segment-Level Information |
The following table presents selected financial information about the Company’s single operating segment. The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM for the three and six months ended June 30, 2026 and 2025 (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration revenue |
|
$ |
6,314 |
|
|
$ |
10,130 |
|
|
$ |
13,538 |
|
|
$ |
18,948 |
|
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development personnel-related (excluding stock-based compensation) |
|
|
20,405 |
|
|
|
19,279 |
|
|
|
40,218 |
|
|
|
37,290 |
|
External research and development costs - GB-0895 |
|
|
20,490 |
|
|
|
13,280 |
|
|
|
36,076 |
|
|
|
17,074 |
|
External - discovery related costs and other |
|
|
16,879 |
|
|
|
21,122 |
|
|
|
33,337 |
|
|
|
40,292 |
|
General and administrative personnel-related (excluding stock-based compensation) |
|
|
4,545 |
|
|
|
4,457 |
|
|
|
9,185 |
|
|
|
8,888 |
|
External - General and administrative |
|
|
4,147 |
|
|
|
3,332 |
|
|
|
9,318 |
|
|
|
6,740 |
|
Stock-based compensation |
|
|
8,238 |
|
|
|
5,487 |
|
|
|
14,633 |
|
|
|
10,231 |
|
Depreciation expense |
|
|
3,224 |
|
|
|
3,322 |
|
|
|
6,497 |
|
|
|
6,736 |
|
Other segment expenses (a) |
|
|
62 |
|
|
|
31 |
|
|
|
367 |
|
|
|
48 |
|
Interest income |
|
|
(4,629 |
) |
|
|
(3,789 |
) |
|
|
(7,542 |
) |
|
|
(8,070 |
) |
Interest expense |
|
|
155 |
|
|
|
307 |
|
|
|
337 |
|
|
|
675 |
|
Provision for income tax |
|
|
53 |
|
|
|
44 |
|
|
|
81 |
|
|
|
100 |
|
Consolidated net loss |
|
$ |
(67,255 |
) |
|
$ |
(56,742 |
) |
|
$ |
(128,969 |
) |
|
$ |
(101,056 |
) |
Net loss attributable to non-controlling interests |
|
|
- |
|
|
|
(4,313 |
) |
|
|
(268 |
) |
|
|
(6,942 |
) |
Consolidated net loss attributable to Generate Biomedicines, Inc. stockholders |
|
$ |
(67,255 |
) |
|
$ |
(52,429 |
) |
|
$ |
(128,701 |
) |
|
$ |
(94,114 |
) |
(a)Other segment expenses include change in fair value of convertible preferred stock warrant liability and foreign currency exchange loss.
|